Mirxes (HKG:2629) launched its initial public offering in Hong Kong Thursday, seeking to raise up to HK$1.09 billion from the deal.
The Singapore-headquartered micro ribonucleic acid technology company is offering up to 46,620,000 at HK$23.30 per share, according to a Thursday filing with the Hong Kong Stock Exchange.
Mirxes will disclose allocation results on May 22. Shares will begin trading on the stock exchange on May 23.
The micro RNA technology company intends to use the proceeds for research and development for its core cancer screening product GASTROClear and its pipeline products, integration of its end-to-end capabilities, and for working capital.
Mirxes attracted Beijing Xunrui and Evergreen Gate as cornerstone investor.
China International Capital Corp. Hong Kong Securities, CCB International Capital, CMBC Securities, CMB International Capital, Soochow Securities International, Livermore Holdings, BOCOM International Securities, and Platinum Broking, are the joint bookrunners and lead managers of the IPO.
Waton Securities International, Alpha Win Capital, Imperium International Securities, Kingkey Securities Group, and Yuen Meta (International), are also joint lead managers of the offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.